Fludrocortisone Use in Pregnancy
Yes, fludrocortisone can be used during pregnancy when clearly needed, particularly for patients with primary adrenal insufficiency, though dose adjustments are often required during late pregnancy.
FDA Classification and Safety Profile
Fludrocortisone is FDA Pregnancy Category C 1. This means:
- Adequate animal reproduction studies have not been conducted
- Many corticosteroids have shown teratogenicity in laboratory animals at low doses
- Teratogenicity has not been demonstrated in humans
- The drug should be given only if clearly needed 1
Clinical Use in Pregnancy
For Primary Adrenal Insufficiency
Fludrocortisone is routinely continued and often requires dose increases during pregnancy 2. The physiologic rationale includes:
- Rising serum progesterone has anti-mineralocorticoid effects
- Fludrocortisone dose often needs to be increased during late pregnancy 2
- Plasma renin activity (PRA) is not reliable for dose adjustment during pregnancy as PRA normally increases
- Monitor using salt cravings, blood pressure, and serum electrolytes instead 2
Dosing Guidance
The consensus guideline recommends 2:
- Standard non-pregnant dose: 50-200 µg daily
- Adjust based on clinical parameters (not PRA)
- Continue throughout pregnancy
- During delivery: parenteral hydrocortisone should be given (100 mg bolus, repeated every 6 hours if needed)
Important Monitoring and Precautions
Maternal Monitoring
- Regular blood pressure checks
- Serum electrolytes
- Assessment for signs of over- or under-replacement
- Salt intake should be ad libitum 2
Neonatal Considerations
Critical caveat: Infants born to mothers receiving substantial doses of fludrocortisone during pregnancy should be carefully observed for signs of hypoadrenalism 1. Maternal corticosteroid treatment must be carefully documented in the infant's medical records.
Clinical Context
The evidence shows fludrocortisone has been used successfully in pregnancy, including a case report of its use for maintaining blood pressure in moyamoya disease during pregnancy 3. However, this represents off-label use beyond adrenal insufficiency.
For patients with primary adrenal insufficiency, the risk of untreated disease (adrenal crisis, maternal mortality) far outweighs theoretical fetal risks, making continuation of fludrocortisone essential for maternal and fetal survival 2.